Covered recipient · General Payments record
DAVID A NASRAZADANI
Allopathic & Osteopathic Physicians Ophthalmology
General Payments · PY2019–2024
$1,515.49
- Reported across 36 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $586.71 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $233.47 | 8 |
| Regeneron Healthcare Solutions, Inc. | $158.23 | 2 |
| Bausch & Lomb Americas Inc. | $114.23 | 2 |
| Genentech USA, Inc. | $61.39 | 4 |
| Alcon Laboratories Inc | $19.39 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.27 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105102355 | CMS |
| ABBVIE INC. | $19.08 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105102357 | CMS |
| ABBVIE INC. | $16.42 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105102359 | CMS |
| ABBVIE INC. | $19.72 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105102361 | CMS |
| ABBVIE INC. | $119.13 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105102363 | CMS |
| ABBVIE INC. | $9.41 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105102365 | CMS |
| ABBVIE INC. | $13.00 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105102367 | CMS |
| ABBVIE INC. | $18.44 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105102369 | CMS |
| Alcon Vision LLC | $19.39 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110695047 | CMS |
| Bausch & Lomb Americas Inc. | $100.37 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140332413 | CMS |
| Bausch & Lomb Americas Inc. | $13.86 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140332411 | CMS |
| Genentech USA, Inc. | $13.19 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132998335 | CMS |
| Genentech USA, Inc. | $15.74 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132998322 | CMS |
| Genentech USA, Inc. | $17.91 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132998326 | CMS |
| Genentech USA, Inc. | $14.55 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132998331 | CMS |
| Regeneron Healthcare Solutions, Inc. | $123.80 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114122655 | CMS |
| Regeneron Healthcare Solutions, Inc. | $34.43 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114122657 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.